Conditions: Chronic Kidney Disease
Keywords: Epoetin alfa, ESA, HX575, CKD
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 417
Healthy volunteers: no

Brief summary:
The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)

Detailed description:

Arms:
arm 1: Single arm

Interventions: intervention 1: HX575 epoetin alfa (Sandoz)
Intervention descriptions: intervention 1: Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.

Protocol document: